V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240012353 | 240008553 | 1.6 | 61 | Palliative (P) | 2018-04-25 | 2018-05-06 | TRASTUZUMAB | N | N | 240001549 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 240012354 | 240008557 | 1.58 | 94.4 | Palliative (P) | 2016-07-19 | 2016-07-19 | Brentuximab | N | N | 240001588 | BRENTUXIMAB |
| 240012357 | 240008558 | 1.67 | 64 | Curative (C) | 2018-08-17 | 2018-08-21 | Hydroxycarbamide | N | N | 240001683 | DA |
| 240012358 | 240008559 | 1.73 | null | Palliative (P) | 2015-07-01 | 2015-07-04 | Carboplatin + Etoposide iv&po | 02 | N | 240001943 | FLAG + IDARUBICIN |
| 240012359 | 240008559 | 1.78 | 97 | Palliative (P) | 2014-07-12 | 2014-07-22 | Cisplatin + Etoposide po&iv 3 day | N | N | 240001943 | CYTARABINE |
| 240012360 | 240008561 | null | 65 | Curative (C) | 2016-05-10 | 2016-05-17 | Chlorambucil | N | N | 240002013 | CHLORAMBUCIL |
| 240012361 | 240012575 | 1.6 | 92.2 | null | 2018-05-28 | 2018-05-29 | Brentuximab Vedotin | 02 | N | 240002013 | BRENTUXIMAB |
| 240012362 | 240015900 | 1.6 | null | Palliative (P) | 2015-06-26 | 2015-07-03 | DHAP | 2 | null | 240002201 | GDP |
| 240012363 | 240015900 | null | 0 | Neo-adjuvant (N) | 2017-06-18 | 2017-06-19 | Chlorambucil + Pred + Rituximab | N | N | 240002201 | CHLORAMBUCIL + RITUXIMAB |
| 240012364 | 240016270 | 1.77 | 101.6 | Curative (C) | 2016-03-13 | 2016-03-26 | R IVAC | N | N | 240002309 | CARBOPLATIN + ETOPOSIDE |
| 240012365 | 240016270 | 1.77 | 105 | Palliative (P) | 2015-08-18 | 2015-09-02 | Cytarabine Low Dose | N | null | 240002309 | METHOTREXATE |
| 240012366 | 240008566 | 1.8 | 96.4 | Curative (C) | 2016-05-28 | 2016-06-01 | Bortezomib (weekly) | N | N | 240002319 | DHAP |
| 240012367 | 240008566 | 1.57 | 90 | Curative (C) | 2017-10-03 | 2017-10-10 | Hydroxycarbamide | 2 | N | 240002319 | TRASTUZUMAB |
| 240012368 | 240008566 | 1.56 | 86.2 | null | 2014-02-19 | 2015-12-27 | GDP | N | N | 240002319 | R IVAC |
| 240012369 | 240008566 | 1.61 | 44 | Palliative (P) | 2015-06-15 | 2015-06-15 | LENALIDOMIDE | N | N | 240002319 | TRASTUZUMAB |
| 240012370 | 240008567 | 1.73 | 55.9 | Curative (C) | 2018-09-26 | 2018-09-27 | LEAM | N | N | 240002398 | CISPLATIN + TOPOTECAN |
| 240012371 | 240012577 | 1.76 | 122 | Disease modification (D) | 2016-04-08 | 2016-04-15 | RATHL TRIAL | N | N | 240002416 | ESHAP R |
| 240012372 | 240008568 | 1.84 | 82 | Curative (C) | 2014-01-09 | 2014-01-24 | CISPLATIN + GEMCITABINE | N | N | 240002469 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 240012373 | 240008569 | 1.75 | 61 | Curative (C) | 2014-11-21 | 2014-11-25 | IVE | 2 | null | 240002486 | PEMBROLIZUMAB |
| 240012374 | 240012581 | 1.63 | 70 | Curative (C) | 2017-08-19 | 2017-09-03 | Vinorelbine IV | N | N | 240002486 | RCEOP |
| 240012375 | 240008572 | 1.68 | 51.7 | Curative (C) | null | 2014-05-30 | Fludarabine + Melphalan RIC Allo | null | null | 240002594 | RUXOLITINIB |
| 240012376 | 240012582 | 1.64 | 82.4 | Curative (C) | 2016-04-30 | 2016-05-26 | TOPOTECAN | N | null | 240002661 | CYTARABINE + METHOTREXATE + RITUXIMAB |
| 240012377 | 240008573 | 1.76 | null | null | 2017-08-20 | 2018-03-02 | AML Int Guide ADE 8+3+5 (2) | N | null | 240002690 | IVAC |
| 240012378 | 240008573 | 1.64 | 60.5 | Curative (C) | 2017-04-06 | 2017-11-06 | ATG + Busulfan + Fludarabine + Thiotepa | 02 | null | 240002690 | VIOLA TRIAL |
| 240012379 | 240008573 | 1.6 | 70.8 | Curative (C) | 2015-12-26 | 2015-12-27 | Carboplatin + Topotecan | 2 | N | 240002690 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 240012382 | 240008575 | 1.65 | null | Disease modification (D) | 2016-04-12 | 2016-04-12 | R-GEM-P | N | N | 240002854 | TRIFLURIDINE + TIPIRACIL |
| 240012383 | 240008578 | 1.59 | 70.8 | Disease modification (D) | 2012-05-30 | 2014-06-27 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | N | 240002961 | UKALL60+ |
| 240012385 | 240008582 | 1.66 | null | Palliative (P) | null | 2017-02-27 | VEDex | null | null | 240003041 | CARMUSTINE + THIOTEPA |
| 240012386 | 240008583 | 1.82 | 69 | null | 2015-09-20 | 2015-09-25 | Cladribine (subcut) 5 days | 02 | N | 240003160 | CAPECITABINE + IRINOTECAN |
| 240012387 | 240012586 | null | 81.8 | Curative (C) | 2016-07-10 | 2016-11-01 | CTD | 02 | N | 240003160 | IMATINIB |
| 240012388 | 240008585 | null | null | Palliative (P) | 2017-01-08 | 2017-01-09 | VEDex | N | N | 240003250 | ACE |
| 240012389 | 240008586 | 1.75 | 53.4 | Curative (C) | 2013-07-31 | 2013-08-31 | CTD | null | N | 240003545 | DTPACE |
| 240012390 | 240012589 | null | 105.5 | Palliative (P) | 2014-07-27 | 2014-07-27 | Ipilimumab | 2 | null | 240003545 | CVD |
| 240012391 | 240016149 | 1.75 | 83 | Curative (C) | 2014-10-25 | 2014-10-26 | GEM-P | 02 | null | 240003708 | ICE-R |
| 240012392 | 240016149 | 1.79 | 91.2 | null | 2014-12-10 | 2015-02-07 | R-CHOEP | 02 | null | 240003708 | DOXORUBICIN |
| 240012393 | 240008587 | 1.8 | 95 | Curative (C) | 2016-09-09 | 2016-10-07 | CARMUSTINE + THIOTEPA | 2 | N | 240003818 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 240012394 | 240008589 | 1.54 | null | Neo-adjuvant (N) | 2016-04-18 | 2016-11-04 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 240003921 | IVAC |
| 240012395 | 240008589 | 1.73 | 55.1 | null | 2014-06-09 | 2014-06-11 | CHOEP - 14 days | N | N | 240003921 | CHOEP |
| 240012396 | 240014475 | 0 | 82.8 | Adjuvant (A) | 2017-06-15 | 2017-11-25 | CYTARABINE + ETOPOSIDE | N | N | 240004197 | UKALL60+ |
| 240012397 | 240014475 | null | 68.9 | Disease modification (D) | 2017-08-08 | 2017-08-08 | Cyclophosphamide + Vincristine | N | N | 240004197 | BEACOPP |
| 240012398 | 240014475 | 1.65 | 53 | Not known (9) | 2018-01-28 | 2018-01-28 | CYTARABINE + METHOTREXATE + RITUXIMAB | 2 | N | 240004197 | AML19 TRIAL |
| 240012399 | 240014475 | 1.64 | 53.2 | Palliative (P) | 2016-03-12 | 2016-03-14 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 240004197 | ICE-R |
| 240012400 | 240012592 | 1.71 | 79.5 | Curative (C) | 2016-11-15 | 2016-11-16 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 240004286 | CYTARABINE HD + METHOTREXATE HD |
| 240012401 | 240008592 | 1.83 | 51 | Palliative (P) | 2015-09-29 | 2016-07-19 | DHAP - R | N | N | 240004471 | OFATUMUMAB |
| 240012402 | 240008593 | 1.57 | 100.65 | null | null | 2018-03-14 | Rituximab + Temozolomide | N | null | 240004510 | CVD |
| 240012403 | 240012594 | null | 73.3 | Adjuvant (A) | 2014-10-20 | 2014-11-21 | Cytarabine High Dose | null | null | 240004651 | GALLIUM TRIAL |
| 240012404 | 240008595 | 1.75 | 87.7 | Palliative (P) | 2017-10-03 | 2017-10-15 | CARMUSTINE + THIOTEPA | 02 | N | 240004667 | AML18 TRIAL |
| 240012407 | 240012596 | 1.73 | null | Curative (C) | 2014-04-25 | 2014-05-02 | IGEV R | N | N | 240004826 | CVD |
| 240012408 | 240008599 | 1.59 | 68.7 | Curative (C) | 2015-06-28 | 2015-06-30 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | N | N | 240004839 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 240012409 | 240015905 | 1.78 | 52.5 | Unknown (U) | 2013-09-30 | 2013-10-02 | FEC 100 | N | N | 240005033 | VINCRISTINE |